Michael Levy MD, PhDAssociate Professor of Neurology, Harvard Medical School; Research Director, Division of Neuroimmunology and Neuroinfectious Disease, Massachusetts General Hospital, Boston, Massachusetts
Dr. Michael Levy, MD, PhD, is an Associate Neurologist at Massachusetts General Hospital and Research Director of the Division of Neuroimmunology & Neuroinfectious Disease. He completed the MD/PhD program at Baylor College of Medicine (Houston, TX) with a focus on neuroscience. Dr. Levy completed his Johns Hopkins internship in the Osler Medicine program, residency in the Johns Hopkins Neurology program and a fellowship in Neuroimmunology at Johns Hopkins University. In 2009, Dr. Levy was appointed to the faculty as Assistant Professor at Johns Hopkins where he started the Neuromyelitis Optica Clinic and Research Laboratory, and in 2019 he moved to the Massachusetts General Hospital and Harvard Medical School to develop the research program in neuroimmunology.
Clinically, Dr. Levy specializes in taking care of patients with rare neuroimmunological diseases including neuromyelitis optica, transverse myelitis, MOG antibody disease, acute disseminated encephalomyelitis and optic neuritis. In addition to neuroimmunology clinics, Dr. Levy has a special interest in patients with superficial siderosis of the central nervous system. Dr. Levy is the principal investigator on several clinical studies and drug trials for all of these conditions.
In the laboratory, Dr. Levy’s research focuses on the development of animal models of neuromyelitis optica and transverse myelitis with the goal of tolerization as a sustainable long-term treatment.
DisclosuresDr. Levy has received consulting fees from Alexion, Viela Bio, Genentech/Roche/Chugai, Quest Diagnostics, and UCB Pharmaceuticals.
Recent Contributions to PracticeUpdate:
- Efficacy and Safety of Ravulizumab in Patients With Aquaporin-4–Positive NMOSD
- Prolonged Fever in MOG Antibody–Associated Disorders
- NMOSD: Pregnancy-Related Attack and Predictive Risk Factors
- Safety and Efficacy of Tocilizumab vs Azathioprine in Highly Relapsing Neuromyelitis Optica Spectrum Disorder
- Safety and Efficacy of Satralizumab Monotherapy in Neuromyelitis Optica Spectrum Disorder
- Satralizumab Reduces Relapse in Neuromyelitis Optica Spectrum Disorder
- Short Delay to Initiate Plasma Exchange Predicts Outcome in Severe Attacks of NMO Spectrum Disorders
- Long-Term Remission of Neuromyelitis Optica After Ending Rituximab Treatment
- Tolerability and Efficacy of Mycophenolate Mofetil in Neuromyelitis Optica Spectrum Disorder